Absci (ABSI) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.20
- Surprise
- —
- Revenue (period 2026-06-30)
- $318,000
- Score today
- 4.5/10
Revenue source: xbrl.
Coverage in the report window
- National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower — benzinga, 2026-08-12
- Needham Reiterates Buy on Absci, Maintains $11 Price Target — benzinga, 2026-08-12
- BTIG Reiterates Buy on Absci, Maintains $13 Price Target — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates ABSI Sell at 4.5/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-16.
What argues against it
- Concentration risk — Customer: partnered drug creation programs
- Quality below floor (1.5 < 4.0)
- Value-trap signals (3/5): Revenue declining (-90.6% YoY), Margin compression (op margin -567.2%), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.24
- Price target
- $12.53
- Stop
- $8.60
- Upside to target
- +35.5%
- Reward-to-risk
- 2.4:1
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
ABSI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.76B
- P/E (fwd)
- -15.2
- 52-week range
- $2.24–$12.05
- Off 52-week high
- 23.3%
- RSI (14)
- 50
- Volume vs avg
- 0.67×
- Score today
- 4.5/10